Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.
暂无分享,去创建一个
J. Baird | H. Myint | Jonathan Berman | L. Walker | C. Ohrt | B. Pybus | V. Meléndez
[1] R. Price,et al. Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Laura Dickinson,et al. Grapefruit-Drug Interactions , 2010, Drugs.
[3] Elizabeth Ashley,et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.
[4] B. Tekwani,et al. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. , 2009, Toxicology and applied pharmacology.
[5] M. Marselos,et al. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity , 2009, Archives of Toxicology.
[6] Ernest Beutler,et al. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. , 2007, The American journal of tropical medicine and hygiene.
[7] A. Magill,et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. , 2006, The American journal of tropical medicine and hygiene.
[8] S. Prusiner,et al. QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN , 2006, Drug Metabolism and Disposition.
[9] K. Rieckmann,et al. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? , 2006, British journal of clinical pharmacology.
[10] Anders Björkman,et al. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data , 2003, European Journal of Clinical Pharmacology.
[11] P. Beaune,et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[12] P. Rosenthal. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. , 2002 .
[13] S. Croft. Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery. , 2001, Drug discovery today.
[14] G. Edwards. Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery , 2001 .
[15] V. do Rosário,et al. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. , 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[16] Purnomo,et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. , 1995, The American journal of tropical medicine and hygiene.
[17] N. White,et al. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. , 1993, British journal of clinical pharmacology.
[18] H. Frischer,et al. The conversion of primaquine into primaquine-aldehyde, primaquine-alcohol, and carboxyprimaquine, a major plasma metabolite. , 1991, The Journal of laboratory and clinical medicine.
[19] S. Meshnick,et al. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. , 1990, The American journal of tropical medicine and hygiene.
[20] A. Tarlov,et al. The hemolytic effect of primaquine. XV. Role of methemoglobin. , 1962, The Journal of laboratory and clinical medicine.
[21] R. J. Dern,et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. , 1955, The Journal of laboratory and clinical medicine.
[22] C. Clayman,et al. 3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .
[23] E. Yount,et al. Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (SN-11,437) and with sulfadiazine. , 1948, Journal. National Malaria Society.
[24] Yount Eh,et al. Reactions observed during treatment with pentaquine, administered with quinacrine (atabrine) metachloridine (SN-11,437) and with sulfadiazine. , 1948 .
[25] C. Whorton,et al. THE TOXICITY OF LARGE DOSES OF PENTAQUINE (SN-13,276), A NEW ANTIMALARIAL DRUG. , 1948, The Journal of clinical investigation.
[26] D. Earle,et al. STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. IX. EFFECT OF PAMAQUINE ON THE BLOOD CELLS OF MAN. , 1948, The Journal of clinical investigation.
[27] C. Zubrod,et al. STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VIII. THE PHYSIOLOGICAL DISPOSITION OF PAMAQUINE. , 1948, The Journal of clinical investigation.
[28] C. Whorton,et al. PENTAQUINE (SN-13,276), A THERAPEUTIC AGENT EFFECTIVE IN REDUCING THE RELAPSE RATE IN VIV AX MALARIA. , 1948, The Journal of clinical investigation.
[29] C. Whorton,et al. Clinical Standardization of Pamaquin (Plasmochin) in Mosquito-Induced Vivax Malaria, Chesson Strain: A Preliminary Report1 , 1947 .
[30] Organización Mundial de la Salud. Guidelines for the treatment of malaria , 2010 .
[31] Draft Guidance,et al. Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , and Implications for Dosing and Labeling DRAFT GUIDANCE , 2006 .
[32] P. Beaune,et al. IN VITRO METABOLISM OF CHLOROQUINE : IDENTIFICATION OF CYP 2 C 8 , CYP 3 A 4 , AND CYP 2 D 6 AS THE MAIN ISOFORMS CATALYZING N-DESETHYLCHLOROQUINE FORMATION , 2003 .
[33] C. Dutton,et al. 8-Aminoquinolines as anticoccidials--II. , 1997, Bioorganic & Medicinal Chemistry Letters.
[34] R. J. Dern,et al. The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1981, The Journal of laboratory and clinical medicine.
[35] A. Lysenko. Use of quinocide in treatment and prophylaxis of vivax malaria. , 1960, Bulletin of the World Health Organization.
[36] Lysenko Ay. Use of quinocide in treatment and prophylaxis of vivax malaria. , 1960 .
[37] C. Clayman,et al. Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.
[38] B. Craige,et al. Pentaquine (SN-13,276) a therapeutic agent effective in reducing the relapse rate in vivax malaria. , 1948, The Journal of clinical investigation.
[39] C. Zubrod,et al. Studies on the chemotherapy of the human malarias; the physiological disposition of pamaquine. , 1948, Journal of Clinical Investigation.